Ascentage Pharma Group International
AAPGNASDAQHealthcare● Active
$17.09
$-0.11(-0.64%)
Market Cap$1.6B
P/E Ratio—
52W High$48.45
52W Low$16.95
Ascentage Pharma Group International (AAPG) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AAPG · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.56B | $0.98B | $0.22B | $0.21B | $0.03B |
| Cost of Revenue | $0.13B | $0.03B | $0.03B | $0.02B | $0.00B |
| Gross Profit | $0.43B | $0.95B | $0.19B | $0.19B | $0.02B |
| Gross Margin %(computed) | 76.41% | 97.03% | 86.24% | 89.51% | 88.08% |
| Operating Expenses | |||||
| R&D Expenses | $1.08B | $0.95B | $0.71B | $0.74B | $0.77B |
| G&A Expenses | $0.00B | $0.19B | $0.18B | $0.17B | $0.14B |
| Total Operating Expenses | $1.61B | $1.32B | $1.06B | $1.04B | $0.96B |
| Operating Income | ($1.18B) | ($0.37B) | ($0.87B) | ($0.85B) | ($0.87B) |
| Operating Margin %(computed) | -211.14% | -37.70% | -393.11% | -405.23% | — |
| Interest Income | $0.08B | $0.04B | $0.03B | $0.01B | $0.01B |
| Interest Expense | $0.05B | $0.06B | $0.10B | $0.05B | $0.02B |
| Income Before Tax | ($1.20B) | ($0.40B) | ($0.93B) | ($0.89B) | ($0.83B) |
| Income Tax Expense | $0.01B | $0.01B | ($0.01B) | ($0.00B) | ($0.05B) |
| Net Income | ($1.21B) | ($0.41B) | ($0.93B) | ($0.88B) | ($0.78B) |
| Net Margin %(computed) | -216.47% | -41.34% | -416.98% | -421.02% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-13.56 | $-5.36 | $-52.48 | $-53.60 | $-49.12 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.02B | 0.02B | 0.02B |
| EBITDA | ($1.10B) | ($0.24B) | ($0.74B) | ($0.79B) | ($0.80B) |
| EBITDA Margin %(computed) | -196.08% | -24.23% | -334.98% | -375.26% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more Ascentage Pharma Group International data
About Ascentage Pharma Group International (AAPG) Income Statement
Ascentage Pharma Group International (AAPG) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AAPG reported revenue of $0.56B, gross profit of $0.43B (gross margin 76.41%), and net income of ($1.21B) — a net profit margin of -216.47%.
Frequently asked questions
AAPG · 4 questionsAscentage Pharma Group International (AAPG) reported revenue of $0.56B for 2025, down 43.1% year-over-year.
AAPG revenueAAPG salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08